Insurance Firm BCS Partners With NHF to Improve Healthcare Quality, Cost

Insurance Firm BCS Partners With NHF to Improve Healthcare Quality, Cost
5
(1)

The healthcare insurance company BCS Financial has partnered with the National Hemophilia Foundation (NHF) to improve care quality and cost for people with hemophilia.

BCS Financial provides services primarily for Blue Cross and Blue Shield organizations and their customers. The NHF is a nonprofit that supports the development of treatments and the prevention of complications for people with inheritable bleeding disorders through research, advocacy, and education. 

“The partnership with NHF, a trusted advocacy organization aligned with our focus on assisting with quality and cost of care, is a first-of-its-kind in the industry,” Peter Costello, president and CEO of BCS, said in a press release

“NHF’s unique ability to advise on optimal care management truly benefits our customers not only with cost but the level of service we strive to provide,” he added. 

Hemophilia is caused by missing or defective clotting factors, proteins needed for normal blood clotting. Each type of hemophilia results from deficiency in one specific clotting factor. 

A primary treatment option for hemophilia patients is replacement therapy, which supplies the missing clotting protein during bleeding episodes (on-demand) or by regular injections to prevent bleeds (prophylaxis). 

Other treatments include desmopressin — a man-made version of the naturally occurring hormone vasopressin — medicines called antifibrinolytics to prevent or slow the breakdown of blood clots, and bypassing agents used when replacement factors induce an immune response. 

Hemophilia ranks in the top 10 highest case spends, with costs of several hundred thousand dollars per year and annual expenses than can exceed $1 million for people with the most severe forms of the disease, according to the NHF.  

Three major factors drive costs in hemophilia: the site of hemophilia care, testing (assay) management, and prescription management. 

The partnership between BCS and NHF will address these factors by providing patients with increased access to BCS and its complementary services, including limited benefit, international health, excess of loss, stop loss, and group supplemental insurance.

“The partnership between the NHF and BCS and its member plans allow us to establish baseline data on payment claims for people with hemophilia and develop strategies for Blue payers to facilitate the delivery of high-quality care through the network of federally-funded hemophilia treatment centers,” said Leonard A. Valentino, MD, president and CEO of the NHF. “BCS supports our goal to ensure optimal patient outcomes at the lowest possible cost.”

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Total Posts: 46

José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

×
Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Latest Posts
  • Rixubis, switching
  • Esperoct and Hem A
  • Eloctate
  • NHF, BCS partnership

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?